Effects of Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease—A Meta-Analysis
出版年份 2020 全文链接
标题
Effects of Resveratrol Supplementation in Patients with Non-Alcoholic Fatty Liver Disease—A Meta-Analysis
作者
关键词
-
出版物
Nutrients
Volume 12, Issue 8, Pages 2435
出版商
MDPI AG
发表日期
2020-08-13
DOI
10.3390/nu12082435
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Effect of resveratrol on non‑alcoholic fatty liver disease
- (2019) Marios Theodotou et al. Experimental and Therapeutic Medicine
- Non-alcoholic fatty liver disease in non-obese individuals: Prevalence, pathogenesis and treatment
- (2019) Emilio Molina-Molina et al. Clinics and Research in Hepatology and Gastroenterology
- Resveratrol Reduces Glucolipid Metabolic Dysfunction and Learning and Memory Impairment in a NAFLD Rat Model: Involvement in Regulating the Imbalance of Nesfatin-1 Abundance and Copine 6 Expression
- (2019) Xing-Xing Chen et al. Frontiers in Endocrinology
- Diet-Induced Rat Model of Gradual Development of Non-Alcoholic Fatty Liver Disease (NAFLD) with Lipopolysaccharides (LPS) Secretion
- (2019) Dominika Maciejewska et al. Diagnostics
- No effect of resveratrol on VLDL-TG kinetics and insulin sensitivity in obese men with nonalcoholic fatty liver disease
- (2018) Marianne K. Poulsen et al. DIABETES OBESITY & METABOLISM
- Comparison of Calorie-Restricted Diet and Resveratrol Supplementation on Anthropometric Indices, Metabolic Parameters, and Serum Sirtuin-1 Levels in Patients With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial
- (2018) Somayyeh Asghari et al. JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION
- Non-alcoholic fatty liver disease (NAFLD) – epidemic of the XXI century
- (2018) Dominika Maciejewska et al. Postepy Higieny I Medycyny Doswiadczalnej
- Systematic Review and Meta-Analysis Resveratrol supplementation in patients with non-alcoholic fatty liver disease: systematic review and meta-analysis
- (2017) Journal of Gastrointestinal and Liver Diseases
- Alternative treatment methods attenuate the development of NAFLD: A review of resveratrol molecular mechanisms and clinical trials
- (2017) Tomasz Charytoniuk et al. NUTRITION
- Association of blood pressure level with nonalcoholic fatty liver disease in nonhypertensive population
- (2016) Lin-Yan Qian et al. MEDICINE
- Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease
- (2016) Sara Heebøll et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Efficacy of Resveratrol Supplementation against Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Placebo-Controlled Clinical Trials
- (2016) Chongyang Zhang et al. PLoS One
- The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study
- (2015) Forouzan Faghihzadeh et al. BRITISH JOURNAL OF NUTRITION
- Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial
- (2015) Shihui Chen et al. DIGESTIVE AND LIVER DISEASE
- Properties of Resveratrol:In VitroandIn VivoStudies about Metabolism, Bioavailability, and Biological Effects in Animal Models and Humans
- (2015) J. Gambini et al. Oxidative Medicine and Cellular Longevity
- Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease
- (2014) Veronique S. Chachay et al. Clinical Gastroenterology and Hepatology
- Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease
- (2014) Forouzan Faghihzadeh et al. NUTRITION RESEARCH
- Effects of resveratrol and other polyphenols in hepatic steatosis
- (2014) Leixuri Aguirre WORLD JOURNAL OF GASTROENTEROLOGY
- Anti-Inflammatory and Antioxidant Effects of Resveratrol in Healthy Smokers A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial
- (2013) S. Bo et al. CURRENT MEDICINAL CHEMISTRY
- Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD
- (2013) Amedeo Lonardo et al. CURRENT PHARMACEUTICAL DESIGN
- The global NAFLD epidemic
- (2013) Rohit Loomba et al. Nature Reviews Gastroenterology & Hepatology
- High-Dose Resveratrol Supplementation in Obese Men: An Investigator-Initiated, Randomized, Placebo-Controlled Clinical Trial of Substrate Metabolism, Insulin Sensitivity, and Body Composition
- (2012) M. M. Poulsen et al. DIABETES
- Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis
- (2012) Federico Salamone et al. Translational Research
- Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults
- (2011) G. Vernon et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Calorie Restriction-like Effects of 30 Days of Resveratrol Supplementation on Energy Metabolism and Metabolic Profile in Obese Humans
- (2011) Silvie Timmers et al. Cell Metabolism
- Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitis
- (2011) Federico Salamone et al. DIGESTIVE AND LIVER DISEASE
- Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
- (2010) Herbert Tilg et al. HEPATOLOGY
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
- (2009) Alessandro Liberati et al. PLOS MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now